McShane Nicola, Zaborowski Alexandra, O'Reilly Mary, McCartan Damian, Prichard Ruth
St Vincent's University Hospital, Dublin, Ireland.
J Surg Oncol. 2025 Mar;131(4):580-586. doi: 10.1002/jso.27963. Epub 2024 Oct 29.
The global incidence of hormone-positive breast cancer (HR+ BC) in young women is rising, though the underlying reasons remain unclear. HR+ disease in younger women appears to represent a distinct clinical entity compared to that in older women, exhibiting distinct clinicopathological characteristics, outcomes and responses to treatment. Despite these differences, there is a paucity of large-volume data focusing on young women with HR+ in contemporary literature. Hormone receptor positive breast cancer in young women is associated with poorer prognoses compared to older women. Additionally, early age onset breast cancer presents unique challenges, including concerns related to fertility, the toxic effects of therapeutic agents, and specific surgical considerations. The purpose of this review is to report the existing literature on HR+ disease in young women.
年轻女性激素阳性乳腺癌(HR+ BC)的全球发病率正在上升,但其潜在原因尚不清楚。与老年女性相比,年轻女性的HR+疾病似乎代表一种独特的临床实体,具有独特的临床病理特征、预后和对治疗的反应。尽管存在这些差异,但当代文献中针对年轻HR+女性的大量数据却很匮乏。与老年女性相比,年轻女性激素受体阳性乳腺癌的预后较差。此外,早发性乳腺癌带来了独特的挑战,包括与生育、治疗药物的毒性作用以及特定手术考量相关的问题。本综述的目的是报告关于年轻女性HR+疾病的现有文献。